RNA, U4 small nuclear 59, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4-59P profile across patient tissues and cancer cell-line models. RNU4-59P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNU4-59P is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, RNU4-59P RNA expression shows 6,725 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight LIHC, STAD, and BRCA as cancer lineages where RNU4-59P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4-59P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4-59P survival associations across molecular data types. RNU4-59P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4-59P RNA expression–survival associations across cancer types. High RNU4-59P expression shows unfavorable associations in LIHC, ACC, KIRC, UCEC and PAAD, but favorable associations in OV. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNU4-59P RNA expression.
This table summarizes RNU4-59P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4-59P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4-59P shows higher tumor expression in STAD and BRCA. The STAD box plot shows higher RNU4-59P RNA expression in tumor versus normal tissue (log2 FC = +0.238, t-test p = .019).
This table shows molecular features associated with RNU4-59P in patient tissues and cancer cell lines. In patient samples, RNU4-59P shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
